Neracorvir
Neracorvir is an investigational new drug that is being evaluated by Fujian Cosunter Pharmaceutical Company, Ltd. for the treatment of chronic hepatitis B virus (HBV) infections.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Neracorvir is an investigational new drug that is being evaluated by Fujian Cosunter Pharmaceutical Company, Ltd. for the treatment of chronic hepatitis B virus (HBV) infections. It binds to the hepatitis B core (capsid) protein interfering with hepatitis B capsid assembly and viral replication. Neracorvir is sometimes referred to as a HBV core protein modulator, but in HBV, the core and capsid proteins are one in the same.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1367208886 under CC BY-SA 4.0; modifications have been made.